Adherium has announced that Helicon Health, a spin out from the UCL Centre for Health Informatics and Multi Professional Education, will market Adherium’s Hailie inhaler sensors and monitoring service in the UK. According to the Helicon website, the company does three things: 1) “Deliver technological innovations that enable the virtual delivery of healthcare”; 2) “Engineer solutions that help to deliver transformations in healthcare”; and 3) “Partner with Inventors and Innovators to bring new technologies to market.”
The three-year distribution agreement comes shortly after the appointment of Francis White as VP of Global Business Development, the company pointed out. White commented, “This agreement with Helicon presents a significant opportunity to better serve the often-overlooked severe asthma population and give a true and metric driven care pathway for COPD patients. The expertise of the team at Helicon will transform our market access in the UK, give us opportunities in ground-breaking care and accelerate adoption.”
Helicon Health CEO Tony Bowden commented, “This agreement with Adherium marks yet another milestone in our journey towards helping people live longer healthier lives. Supporting people with understanding and complying with the instructions for use of medications is fundamental to achieving the healthcare outcomes people young and old and all in between need –whilst at the same time helping health systems gain the best results from scarce resource.”
In the US, where Adherium launched the Hailie monitoring system in 2018, Monaghan Medical announced an agreement to distribute the Hailie system in certain respiratory centers in 2020. The next generation Hailie sensor received 510(k) clearance in September 2021, and the company recently submitted a 510(k) for a version of the Hailie sensor for use with Ellipta DPIs.
Read the Adherium press release.
